The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Aveo; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Helsinn Therapeutics; Merck Serono; Pfizer
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Marianne Keessen
Employment - Modra Pharmaceuticals
 
Elisabeth I. Heath
Honoraria - Bayer; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; bristol -Myers Squibb; EMD Serono; Exelixis; Gilead Sciences; Hengrui Pharmaceutical; Hinova Pharmaceuticals; Janssen Oncology; Merck; Myovant Sciences; Myovant Sciences; Pfizer; Propella Therapeutics; Seagen; Tavanta Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
Tomas Buchler
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Novartis (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Péter Ferenc Árkosy
No Relationships to Disclose
 
Tibor Csoszi
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Janssen-Cilag
Travel, Accommodations, Expenses - Pfizer; Sanofi
 
Pawel J. Wiechno
No Relationships to Disclose
 
Denis Kholtobin
No Relationships to Disclose
 
Evgeny Kopyltsov
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Aleander Nosov
No Relationships to Disclose
 
Sergey Orlov
No Relationships to Disclose
 
Alexey Plekhanov
No Relationships to Disclose
 
Maria Smagina
No Relationships to Disclose
 
Sergey Varlamov
No Relationships to Disclose
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology